- Home
- NVAX vs MGNI Comparison
NVAX vs MGNI Comparison
Compare NVAX & MGNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVAX
- MGNI
- Stock Information
- Founded
- NVAX 1987
- MGNI 2007
- Country
- NVAX United States
- MGNI United States
- Employees
- NVAX N/A
- MGNI N/A
- Industry
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- MGNI Computer Software: Programming Data Processing
- Sector
- NVAX Health Care
- MGNI Technology
- Exchange
- NVAX Nasdaq
- MGNI Nasdaq
- Market Cap
- NVAX 1.3B
- MGNI 2.4B
- IPO Year
- NVAX 1995
- MGNI N/A
- Fundamental
- Price
- NVAX $6.80
- MGNI $24.26
- Analyst Decision
- NVAX Buy
- MGNI Strong Buy
- Analyst Count
- NVAX 5
- MGNI 13
- Target Price
- NVAX $16.60
- MGNI $20.85
- AVG Volume (30 Days)
- NVAX 5.2M
- MGNI 2.8M
- Earning Date
- NVAX 08-07-2025
- MGNI 08-06-2025
- Dividend Yield
- NVAX N/A
- MGNI N/A
- EPS Growth
- NVAX N/A
- MGNI N/A
- EPS
- NVAX 2.97
- MGNI 0.21
- Revenue
- NVAX $1,254,962,000.00
- MGNI $674,622,000.00
- Revenue This Year
- NVAX $56.85
- MGNI $0.32
- Revenue Next Year
- NVAX N/A
- MGNI $11.02
- P/E Ratio
- NVAX $2.29
- MGNI $114.41
- Revenue Growth
- NVAX 25.92
- MGNI 5.59
- 52 Week Low
- NVAX $5.01
- MGNI $8.22
- 52 Week High
- NVAX $17.81
- MGNI $25.27
- Technical
- Relative Strength Index (RSI)
- NVAX 51.68
- MGNI 86.58
- Support Level
- NVAX $6.23
- MGNI $20.13
- Resistance Level
- NVAX $6.90
- MGNI $24.46
- Average True Range (ATR)
- NVAX 0.30
- MGNI 1.00
- MACD
- NVAX 0.01
- MGNI 0.50
- Stochastic Oscillator
- NVAX 67.00
- MGNI 91.06
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
About MGNI Magnite Inc.
Magnite Inc is one of the supply-side platform providers, or SSP, in online advertising. The firm generate its revenue from the programmatic sale of CTV ad inventory, from mobile online sites and apps, and the remaining from websites accessed via computer.